If Canada were to deploy pharmacogenetic-guided treatments for patients with depression, we would save on average $3,000 per patient. If only 50 per cent of the 1.6 million Canadians with depression were treated based on this method, we would save $2.4-billion per year.
One of the lesser known yet critical issues arising from the disease is its potential effect on drug response and the risk of adverse drug effects.
